Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

BET inhibitor TQB3617

An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, BET inhibitor TQB3617 targets and binds to the acetyl-lysine binding site in the bromodomains (BRDs), thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and suppresses the expression of certain oncogenes, resulting in the inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role in the modulation of gene expression during cellular growth and development.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:TQB 3617
TQB-3617
TQB3617
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search